Program
lazertinib
Also written as “Lazertinib”, “Lazertinib 240 mg/160 mg” and “YH25448”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Osteoarthritis, Knee, led by 4 companies.
Drug pageLazertinib: every studyAll 31 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnsonits history only | 125 open or running | phase 3since Jul 23, 2020 | Aug 21, 2019 | Feb 12, 2027phase 1 · NCT04077463 |
| Yuhan | 40 open or running | phase 3since Jan 14, 2020 | Jan 26, 2017 | none ahead |
| Abionits history only | 11 open or running | phase 2since Sep 4, 2022 | Sep 4, 2022 | Feb 2029phase 2 · NCT05541822 |
| BUZZZ Pharmaceuticalsits history only | 10 open or running | phase 2since Jul 22, 2021 | Jul 22, 2021 | none ahead |
How these companies relate
From the companies’ own releases and filings, each linked; the registry does not say.
- LicenseJanssen (Johnson & Johnson) licensed it from Yuhan, for everywhere outside South Korea.Announced Nov 5, 2018 · Source: Yuhan (release), Nov 5, 2018
How Abion and BUZZZ Pharmaceuticals relate to it is not in the registry or these sources.
History and studies of Yuhan only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). A diamond marks a license, acquisition or co-development, from the companies’ own releases and filings. An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
- Jan 26, 2017First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT03046992 · 224 enrolled · Korea, Republic of
- Jun 9, 2017Named lazertinibINNProposed as its International Nonproprietary Name in WHO's List 117 · before, YH25448
- Jun 1, 2018Phase 1 study in Carcinoma, Non-Small-Cell LungNCT03556436 · 24 enrolled · Korea, Republic of
- Nov 5, 2018Janssen (Johnson & Johnson) licensed it from YuhanLicenseEverywhere outside South Korea · announced · Yuhan (release)
- Jan 14, 2020Phase 3 study in Carcinoma, Non-Small-Cell LungNCT04248829 · 393 enrolled · Australia, Greece, Hungary and more
- Dec 6, 2021Phase 1 study in Carcinoma, Non-Small-Cell LungNCT05162274 · 38 enrolled · Korea, Republic of
TargetBeta
“An orally available third-generation, selective inhibitor of certain forms of the epidermal growth factor receptor (EGFR) with activating mutations, including the resistance mutation T790M, exon 19 deletions (Del19), and the L858R mutation, ”NCIt, by rule
“Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor erbB1 inhibitor; Epidermal growth factor receptor erbB1 inhibitor”ChEMBL 37, by rule
Other programs on EGFR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| izalontamab brengitecan | Sichuan Biokin Pharmaceutical | phase 3 | 55 |
| pimurutamab | Fosun Pharma | phase 3 | 17 |
| Anti-EGFR Antibody-drug Conjugate CPO301 | CSPC Pharmaceutical Group | phase 3 | 16 |
| sunvozertinibrule | Dizal Pharmaceuticals | phase 3 | 12 |
| becotatug | CSPC Pharmaceutical Group | phase 3 | 11 |
| andamertinibrule | avistone-biotechnology-co-ltd | phase 3 | 10 |
| becotatug vedotinrule | lepu-biopharma-co-ltd | phase 3 | 10 |
| sevabertinibrule | Bayer | phase 3 | 8 |
| HS-10504 | Hansoh Pharmaceutical Group | phase 3 | 7 |
| petosemtamabrule | Genmab | phase 3 | 6 |
| bafisontamabrule | shanghai-epimab-biotherapeutics-co-ltd | phase 3 | 5 |
| zipalertinibrule | Otsuka | phase 3 | 4 |
Studies
All 4 Yuhan leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT05162274Carcinoma, Non-Small-Cell Lung · Korea, Republic of | 1 | Completed | Jan 14, 2022 | 38 |
| NCT04248829Carcinoma, Non-Small-Cell Lung · Australia, Greece, Hungary and more | 3 | Completed | Jul 29, 2022 | 393 |
| NCT03556436Carcinoma, Non-Small-Cell Lung · Korea, Republic of | 1 | Completed | Dec 30, 2018 | 24 |
| NCT03046992Carcinoma, Non-Small-Cell Lung · Korea, Republic of | 2 | Completed | Jan 8, 2021 | 224 |
How it is read
Names in the registry
- “Lazertinib”, 12 entries
- “Lazertinib 240 mg/160 mg”, 1 entry
- “YH25448”, 1 entry
- “Lazertinib(G001)”, 1 entry
- “Lazertinib(G002)”, 1 entry
Codes read as this program: G001.
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 10 studies
- Osteoarthritis, Knee, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.